263 related articles for article (PubMed ID: 35875197)
1. Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines.
Li M; Zhang Y; Zhang Q; Li J
Mater Today Bio; 2022 Dec; 16():100364. PubMed ID: 35875197
[TBL] [Abstract][Full Text] [Related]
2. Bioenzyme-based nanomedicines for enhanced cancer therapy.
Ding M; Zhang Y; Li J; Pu K
Nano Converg; 2022 Feb; 9(1):7. PubMed ID: 35119544
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy.
Xu X; Wu Y; Qian X; Wang Y; Wang J; Li J; Li Y; Zhang Z
Adv Healthc Mater; 2022 Jan; 11(1):e2101428. PubMed ID: 34706400
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
5. Boosting antitumor efficacy of nanoparticles by modulating tumor mechanical microenvironment.
Zhang X; Zhang X; Yong T; Gan L; Yang X
EBioMedicine; 2024 Jun; 105():105200. PubMed ID: 38876044
[TBL] [Abstract][Full Text] [Related]
6. Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors.
Han X; Xu Y; Geranpayehvaghei M; Anderson GJ; Li Y; Nie G
Biomaterials; 2020 Feb; 232():119745. PubMed ID: 31918228
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Intracellular Transcytosis of Nanoparticles by Degrading Extracellular Matrix for Deep Tissue Radiotherapy of Pancreatic Adenocarcinoma.
Wang L; Dou J; Jiang W; Wang Q; Liu Y; Liu H; Wang Y
Nano Lett; 2022 Sep; 22(17):6877-6887. PubMed ID: 36036792
[TBL] [Abstract][Full Text] [Related]
8. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
Durymanov MO; Rosenkranz AA; Sobolev AS
Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
[TBL] [Abstract][Full Text] [Related]
9. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
10. Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy.
Zhan M; Yu X; Zhao W; Peng Y; Peng S; Li J; Lu L
J Nanobiotechnology; 2022 Jan; 20(1):23. PubMed ID: 34991618
[TBL] [Abstract][Full Text] [Related]
11. Identification of peptide coatings that enhance diffusive transport of nanoparticles through the tumor microenvironment.
Mohanty RP; Liu X; Kim JY; Peng X; Bhandari S; Leal J; Arasappan D; Wylie DC; Dong T; Ghosh D
Nanoscale; 2019 Oct; 11(38):17664-17681. PubMed ID: 31536061
[TBL] [Abstract][Full Text] [Related]
12. Biomimetic Liposome with Surface-Bound Elastase for Enhanced Tumor Penetration and Chemo-Immumotherapy.
Li YJ; Wu JY; Hu XB; Ding T; Tang T; Xiang DX
Adv Healthc Mater; 2021 Oct; 10(19):e2100794. PubMed ID: 34160137
[TBL] [Abstract][Full Text] [Related]
13. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy.
Henke E; Nandigama R; Ergün S
Front Mol Biosci; 2019; 6():160. PubMed ID: 32118030
[TBL] [Abstract][Full Text] [Related]
15. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy.
Hussain Z; Rahim MA; Jan N; Shah H; Rawas-Qalaji M; Khan S; Sohail M; Thu HE; Ramli NA; Sarfraz RM; Abourehab MAS
J Control Release; 2021 Jul; 335():130-157. PubMed ID: 34015400
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.
Ji B; Wei M; Yang B
Theranostics; 2022; 12(1):434-458. PubMed ID: 34987658
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
18. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
19. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
Guan X; Lin L; Chen J; Hu Y; Sun P; Tian H; Maruyama A; Chen X
J Control Release; 2019 Jan; 293():104-112. PubMed ID: 30476528
[TBL] [Abstract][Full Text] [Related]
20. Engineering extracellular matrix to improve drug delivery for cancer therapy.
He X; Yang Y; Li L; Zhang P; Guo H; Liu N; Yang X; Xu F
Drug Discov Today; 2020 Sep; 25(9):1727-1734. PubMed ID: 32629171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
